Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
“On behalf of the Board of Directors, I am very pleased to welcome
“I am excited to be joining the Board of Directors of Catalyst at such a pivotal time in the company’s evolution, as it continues its effort to broaden its portfolio and product pipeline,” said
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
Catalyst's Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the
David Schull Russo Partners(212) 845-4271 email@example.com Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.